Genetic mutations of SHANK3 have been reported in patients with intellectual disability, autism spectrum disorder (ASD) and schizophrenia. At the synapse, Shank3/ProSAP2 is a scaffolding protein that connects glutamate receptors to the actin cytoskeleton via a chain of intermediary elements. Although genetic studies have repeatedly confirmed the association of SHANK3 mutations with susceptibility to psychiatric disorders, very little is known about the neuronal consequences of these mutations. Here, we report the functional effects of two de novo mutations (STOP and Q321R) and two inherited variations (R12C and R300C) identified in patients with ASD. We show that Shank3 is located at the tip of actin filaments and enhances its polymerization. Shank3 also participates in growth cone motility in developing neurons. The truncating mutation (STOP) strongly affects the development and morphology of dendritic spines, reduces synaptic transmission in mature neurons and also inhibits the effect of Shank3 on growth cone motility. The de novo mutation in the ankyrin domain (Q321R) modifies the roles of Shank3 in spine induction and morphology, and actin accumulation in spines and affects growth cone motility. Finally, the two inherited mutations (R12C and R300C) have intermediate effects on spine density and synaptic transmission. Therefore, although inherited by healthy parents, the functional effects of these mutations strongly suggest that they could represent risk factors for ASD. Altogether, these data provide new insights into the synaptic alterations caused by SHANK3 mutations in humans and provide a robust cellular readout for the development of knowledge-based therapies. Molecular Psychiatry (2012) 17, 71-84; doi:10.1038/mp.2011.57; published online 24 May 2011 Keywords: actin; autism; axonal outgrowth; hippocampus; Shank3; spine
Introduction
Autism spectrum disorders (ASDs) are heterogeneous neurodevelopmental disorders diagnosed on the basis of three behaviorally altered domains: social deficits, impaired language and communication and stereotyped behaviors. ASD affect 1% of the population, with males being affected four times more often than females. [1] [2] [3] Family and twin studies indicate a strong genetic basis for ASD, but the mechanisms of transmission remain largely unknown. Recently, several synaptic genes have been associated with ASD, providing a better idea of the pathways involved. 4 The 22q13 deletion syndrome is characterized by developmental delay, moderate to profound language delay, delay/absence of expressive speech, hypotonia and autistic features that are caused by the loss of the SHANK3 gene located at the tip of this chromosome. 5 The SHANK3 gene can also be altered in patients with ASD, and recently, we have shown that mutations, or the loss of one copy of SHANK3, are associated with autism, whereas the presence of an extra copy of SHANK3 might be associated with Asperger syndrome. 6 The variations identified included de novo deleterious mutations and inherited non-synonymous variations affecting highly conserved amino acids in the ankyrin domain. 6, 7 Although these mutations were inherited from healthy parents, they could contribute to the disorder in combination with other unidentified SHANK3 mutations or in combination with other mutated genes.
The three members of the Shank family (Shank1, 2 and 3) are core components of the postsynaptic density, a highly organized cytoskeletal structure found adjacent to the postsynaptic membrane of excitatory synapses. Shank proteins have ankyrin repeats at their N terminus, followed by a SH3 (Src homology) domain, a PDZ (postsynaptic density 95/discs large/zona occludens-1 homology) domain, a proline-rich region and a SAM (sterile alpha motif) domain at their C-terminal region. [8] [9] [10] All of these domains are involved in protein-protein interactions, linking different glutamate receptors, scaffolding proteins and intracellular effectors to the actin cytoskeleton. Indeed, Shank proteins are associated with NMDA (N-methyl-D-aspartate) receptors via the guanylate kinase-associated protein (GKAP)/postsynaptic density-95 (PSD-95) complex and with type I metabotropic glutamate receptors via Homer in the proline-rich domain. 8, 11, 12 In addition, Shank proteins can bind to several actin-regulatory molecules, such as cortactin, 13, 14 Sharpin, 15 a-fodrin, 16 Abp1, 17 b-Pix 18 and SPAR. 19 The actin cytoskeleton of the dendritic spine is particularly dynamic and has a pivotal role in the formation and the maturation of spines and is also involved in the morphological changes that occur in spines during synaptic plasticity. 20 Thus, Shank proteins and their binding partners are involved in vitro in the regulation of the size and the shape of dendritic spine. [21] [22] [23] To further assess the functional consequences of SHANK3 mutations, we used an overexpression approach in cultured neurons to investigate the molecular mechanisms modulated by Shank3 in synapse formation and axonal outgrowth. We first examined the subcellular localization of the wild-type and mutated Shank3 proteins in fibroblasts and embryonic primary neuronal cultures. Our results show that the truncating mutation strongly affected spine development and morphology, as well as growth cone motility, whereas the de novo mutation Q321R preferentially had an effect in early stages of development. Finally, inherited mutations (R12C and R300C) displayed an intermediate phenotype, with lowered spine induction and maturation, and growth cone motility compared with wild-type Shank3.
Materials and methods

DNA constructs
Full-length rat Shank3 complementary DNA has been used previously. 6 Mutated forms (green fluorescent protein GFP-Shank3
R12C
, GFP-Shank3 R300C and GFPShank3 Q321R ) of GFP-Shank3 were generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Deletion variants of GFP-Shank3 STOP were made by introducing a STOP codon by direct mutagenesis to generate Shank3 mutants lacking the C-terminal part of the protein, corresponding to the mutation frameshift 3915 identified in patients. The monomeric red fluorescent protein (monomeric RFP) construct was generously provided by I Macara (University of Virginia, Charlottesville, VA, USA). C Gauthier-Rouviere (Centre de Recherche en Biochimie Macromoléculaire, Centre National de la Recherche Scientifique Montpellier, France) generously provided the RFP-actin construct. The SureSilencing short-hairpin RNA plasmids cloned in p-RFP-C-RS were purchased from Origene (Rockville, MD, USA). Details of the downregulation experiments are described in the supplementary note.
Antibodies
Primary antibodies were anti-actin (Cytoskeleton Inc., Denver, CO, USA), anti-b-tubulin (Tuj-1, Covance, Princeton, NJ, USA), anti-MAP2 (Chemicon, Temecula, CA, USA), anti-DsRED (Clontech, Palo Alto, CA, USA), anti-GFP (Invitrogen, Carlsbad, CA, USA), anti-phosphopaxillin (Cell Signalling, Danvers, MA, USA), antiShank3 (NeuroMab Facility, Davis, CA, USA), anticortactin and anti-vinculin (Sigma-Aldrich, St Louis, MO, USA). Alexa Fluor 546 and 647 phalloidin were used to stain F-actin (Invitrogen). Secondary antibodies were conjugated to Alexa Fluor 488, 546 and 647 (Invitrogen).
Cell culture and transfection HEK293T and COS-7 cells used for transient transfection were maintained in Dulbecco 0 s modied Eagle 0 s medium supplemented with fetal calf serum and antibiotics. Cells were transfected using calcium phosphate, as previously described. 24 Hippocampal neuronal cultures were prepared and transfected with the different constructs using the calcium phosphate method. 24, 25 Immunocytochemistry After 4 days, cells were fixed with 4% paraformaldehyde (PFA), washed, permeabilized with 0.1%. Triton/phosphate-buffered saline (PBS) or 0.05% saponin/PBS, blocked for 1 h with 10% normal goat serum (NGS) or 3% bovine serum albumin (BSA) before incubating for 1.5 h with primary antibodies at room temperature in 3% NGS/PBS or in 0.2% BSA/PBS, then washed in PBS and incubated with secondary antibodies in 3% NGS/PBS or in 0.2% BSA/PBS. Then, phalloidin was incubated for 1 h in 0.2% BSA/PBS.
Protein, western blots, immunoprecipitation
Protein preparation, western blots and immunoprecipitation were performed, as described, 26 and detailed in the supplementary note.
Ratio of F-to G-actin
The amount of F-actin and G-actin was measured with an Actin Polymerization Assay kit (BK037-Cytoskeleton). HEK293T cells were co-transfected with RFP-actin and GFP-C3 (control) or GFPShank3
WT or GFP-Shank3
STOP
. Two days after transfection, the cells were resuspended in F-actin stabilization buffer with adenosine triphosphate (1 mM) SHANK3 mutations in autism and spine morphology CM Durand et al and protease inhibitors (10 Â ). To preserve F-actin, experiments were performed at 37 1C. F-actin was pelleted by a 1-hr centrifugation at 100 000 Â g, and the supernatant (G-actin) was separated. The pellet was resuspended in the same volume as the supernatant using ice-cold Milli-Q water and 10 mM cytochalasin D for 2 h at 4 1C. Actin was quantified by western blot using an anti-actin antibody (Cytoskeleton). The ratio of F-actin to G-actin was determined using an Odyssey infrared imaging system (LI-COR Biosciences, Nebraska, USA).
Microscopy and quantitative analyses of spine morphology Confocal images were acquired with a Leica DMR TCS SP2 AOBS confocal microscope (Leica, France), using the 60 Â objective. Each image was a z-series projection taken at 0.02-mm-deep intervals. The morphometric measurements (width and length of spine) were made using Volocity analysis software (PerkinElmer, MA, USA). Each experiment was performed on five to seven independent neuronal preparations. Cells were co-transfected with monomeric RFP to visualize detailed morphology and to outline the spines. To determine spine size, 1500-1800 spines (from 16-28 neurons) were measured for each condition. For spine length, the distance from the base of the neck to the spine head was measured, and for spine width, the maximal width of the spine head perpendicular to the length was measured. To determine spine density, 10 regions of 20 mm were averaged per neuron.
To quantify F-actin and cortactin in spines, immunofluorescence images were acquired on a DM6000 Leica microscope equipped with MetaMorph software (Molecular devices, Sunnyvale, CA, USA). The fluorescence intensity of F-actin or cortactin was measured as the average intensity in the manually area-represented head of the spine. Each experiment was performed on four to six independent neuronal preparations, and 20-38 neurons were measured for each condition.
Electrophysiology
Neurons (DIV17) co-transfected with GFP and the plasmids of interest were selected based on their fluorescence, and miniature excitatory synaptic current (mEPSC) were recorded, as previously published. 22 Briefly, the recording pipettes had a resistance of 5-10 MW when filled with the following medium (in mM): 140 CsCl, 0. 
Live imaging
Four days after transfection, growth cones of neurons transfected at DIV2 were analyzed by imaging every 2 s for 10 min with an Olympus IX71 inverted microscope (Olympus, France) using a 60 Â oil immersion objective (n = 35-67 growth cones from five independent experiments). The growth cone motility index was calculated, as previously described.
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Statistical significance Data are shown as the mean ± s.e.m. The statistical significance of the results was analyzed using oneway analysis of variance in all experiments. For electrophysiological studies, we used the non-parametric Kruskal-Wallis test for more than two independent small samples.
Results
One of the aims of this study was to evaluate the contribution of Shank3 gene mutations to the actin dynamics-dependent formation of dendritic spines. For this purpose, we studied SHANK3 mutations identified in patients with ASD. 6, 7 Among these mutations (Figure 1a ), one is a frameshift mutation at position 3680 in human SHANK3 complementary DNA (3915 in rat), which introduces a premature STOP codon at position 1227 in humans (1304 in rat), leading to a truncated form of Shank3 (Shank3 STOP ). The remaining three mutations are non-synonymous mutations located in or near the highly conserved ankyrin domain (R12C, R300C and Q321R, referred to as Shank3
R12C
, Shank3 R300C and Shank3
Q321R
, respectively). 6, 7 An immunoblot analysis of the different constructs revealed that the fusion proteins carrying the point mutations Shank3 R12C , Shank3 R300C and Shank3 Q321R had similar levels of expression and size as the GFP-Shank3 WT , whereas the frameshift mutation (Shank3 STOP ) led to a shorter protein ( Figure 1b ).
Decreased clustering of mutated Shank3 at the tips of actin filaments
We first analyzed the intracellular localization of Shank3 WT in COS-7 cells (Figure 1c ). Shank3 WT was found at the plasma membrane and in large intracellular clusters, as previously reported in HEK cells. 29 Interestingly, we noticed that Shank3 clustered at the tips of actin filaments and colocalized with vinculin or phospho-paxillin, two focal adhesion proteins ( Figure  1c ). Overexpression of Shank3 R12C , Shank3 R300C and Shank3 Q321R in COS-7 showed that mutations in the ankyrin domain did not affect the localization of Shank3 at the membrane or in intracellular clusters (Figure 1d ). However, the distribution of Shank3 STOP was restricted to small aggregates around the nucleus, suggesting that the lack of the C terminus in Shank3 affected its targeting and its interaction with the actin cytoskeleton in COS-7 cells. The analysis of the colocalization of Shank3 with actin stress fibers showed that S h a n k 3 S h a n k 3 S h a n k 3 S h a n k 3 S h a n k 3
S h a n k 3 W T S h a n k 3 S T O P IP β-Actin Shank3 S h a n k 3 I g G I n p u t 
GFP-Shank3
WT S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 ; ***P < 0.001, 48±3% for Shank3 Q321R ; *P < 0.05; Figure 1e ). Shank3 STOP was almost completely absent at the tips of actin filaments (10±7% for Shank3 STOP ; ***P < 0.001).
Shank3 binds actin and positively affects actin polymerization As Shank proteins and their partners are involved in actin regulation 13, 18, 30 and Shank3 colocalizes with actin fibers, we performed a coimmunoprecipitation using hippocampal tissue to demonstrate the existence of Shank3-actin complexes in vivo (Figure 1f ). In addition, we used an actin polymerization assay to measure and compare the F-to G-actin ratio in GFP-Shank3-or GFP-C3-transfected cells (Figures 1g  and h ). In this assay, RFP-actin was co-transfected with each construct to stimulate actin polymerization. We analyzed the Shank3 STOP construct because this mutated protein does not colocalize with actin filaments. Overexpression of Shank3
WT significantly increased the amount of F-actin (1.399 ± 0.039) compared with the control (***P < 0.001; Figures 1g and  h) , showing the role of Shank3
WT in in vitro actin polymerization. In contrast, no significant difference in actin polymerization was observed with Shank3 STOP protein (0.971±0.062; P > 0.05) compared with the control. These results suggest that the C terminus of Shank3 is crucial for actin dynamics.
Shank3 mutations affect spine induction and spine morphology
To analyze the role of Shank3 in actin cytoskeleton regulation in dendritic spines, we overexpressed the different constructs in hippocampal neurons and studied their effects on the organization and shape of postsynaptic spines. First, we analyzed the subcellular localization of the different Shank3 mutants co-transfected with an RFP plasmid in hippocampal neurons. Shank3
WT overexpression led to an accumulation of the protein in dendritic spines (Figure 2a) , as previously reported. 31 Point mutations (Shank3 R12C , Shank3
R300C and Shank3
Q321R
) did not affect this synaptic targeting. As observed in COS-7 cells, Shank3 STOP accumulated in the soma, was weakly localized in the dendrites and was absent from dendritic spines, indicating that the C terminus was required for the dendritic targeting of Shank3. These results are consistent with previous data showing that the Homer-binding site is involved in the synaptic localization of Shank3. 22, 31 In addition, Shank3
WT significantly increased the number of spines compared with the control ( Figure  2b ) and reduced the number of filopodia (Figure 2c ) in rat hippocampal neurons. The number of spines per 20 mm of dendrite length was 6.3 ± 0.4 spines when Shank3
WT was overexpressed compared with 3.4±0.3 spines in control GFP-positive neurons (***P < 0.001).
Overexpression of Shank3 R12C , Shank3 R300C or Shank3 Q321R also increased the number of spines, but not as much as Shank3 WT (4.6±0.3, 4.7 ± 0.3 or 5.0 ± 0.2 spines per 20 mm, respectively; **P < 0.01 and ***P < 0.001 compared with control). The mutations in the ankyrin domain therefore had moderate effects on spine induction, but still significantly lower than Shank3 WT (1P < 0.05; 11P < 0.01 and 111P < 0.001, respectively). The overexpression of Shank3 STOP had a stronger effect, with a reduction in the number of spines compared with Shank3
WT and with the control (2.6 ± 0.2 spines per 20 mm; 111P < 0.001 compared with Shank3
WT and *P < 0.05 WT enhances the polymerization of actin (***P < 0.001; n = 6 independent experiments). Shank3
STOP inhibits the effect of Shank3 on actin polymerization. Figure 1) . Altogether, our results suggest that Shank3 STOP has a dominantnegative effect on spine induction in a wild-type background, probably by affecting the targeting and/ or the stability of the wild-type protein at synapses.
Finally, we investigated the impact of Shank3 mutations on spine maturation and measured spinehead enlargement and spine length from the base to the top of the head in rat hippocampal neurons μm S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P G F P -C 3 S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P WT expressed in aspiny neurons 22 or with Shank1 in hippocampal cells. 21 Compared with the control, Shank3 STOP did not change the width of spine heads (46.6 ± 2% of spines > 0.5 mm; P > 0.5) but reduced the length of the spines (34±2% of spines > 1.0-mm length; *P < 0.05).
Shank3
Q321R showed a slight increase in the width of the spine head (59 ± 2% of spines > 0.5 mm) and a reduction in spine length (34 ± 2% of spines > 1.0 mm; *P < 0.05). This suggests that the Q321R mutation does not abolish the effect of Shank3 on spine maturation but does affect neck retraction. Finally, Shank3 R12C and Shank3 R300C did not increase the size of spine heads (54 ± 4% and 51 ± 3% of spines > 0.5 mm; P > 0.05 compared with control), suggesting that these mutations disrupt the effect of Shank3 on spine morphology. Altogether, our data suggest that Shank3
WT overexpression promotes spine induction and maturation, and that all mutations identified in ASD modify the function of Shank3.
Shank3 mutations affect F-actin content but not cortactin level in dendritic spines
As actin dynamics have key roles in dendrite development and specifically in spine formation and maturation, 32, 33 we further examined the effects of Shank3 mutations on the synaptic levels of F-actin and cortactin (Figure 3) . Cortactin is an F-actinbinding protein enriched in cell matrix contact sites that facilitates the nucleation of new actin branches at the tips of actin filaments. In mature neurons, F-actin appeared in the form of patches and puncta along the dendrites, and it was enriched in the heads of dendritic spines (Figure 3a) . We quantified the level of actin in spine heads as a ratio of the average intensity of transfected neurons to untransfected neurons. We observed an increase in F-actin levels in the spines of Shank3 WT -transfected neurons compared with the control (147±8% for Shank3
WT and 109 ± 6% for the control; **P < 0.01; Figure 3b) ). In the case of the truncating mutation, this was most likely due to a lack of targeting to the spines. Our data show that enlargement of dendritic spines induced by Shank3
WT was correlated with increases in F-actin level. The mutations in the ankyrin domain and the truncated form of Shank3 all affected spines maturation via an actindependent mechanism, as suggested by our fibroblast experiments ( Figure 1) .
As Shank3 binds to cortactin and the loss of cortactin causes a decrease in spine density, 12, 13, 21 we examined the effect of each mutation on cortactin content in dendritic spines. Despite Shank3 mutations significantly reducing the level of F-actin in spines, cortactin level was not significantly different between the control and Shank3 WT (Figure 3c ; P > 0.05).
The Shank3 mutations decrease spontaneous neuronal activity As the number and the morphology of spines might affect the strength of synaptic transmission, we further explored the functional consequences of Shank3 mutations by recording mEPSCs in hippocampal neurons. Shank3
WT had no significant effect on mEPSC amplitude but markedly increased mEPSC frequency compared with GFP-only neurons (1.48 ± 0.08 and 0.74 ± 0.08 Hz, respectively; ***P < 0.001; Figure 4 ). The present correlation between Shank3 WT -mediated changes in spine morphology and electrical activity is in agreement with previous results. STOP to the modulation of synaptic transmission.
The Q321R and STOP mutations affect growth cone motility induced by Shank3 WT Q321R is a de novo mutation identified in a girl with autism, language delay and developmental delay. 7 Here, we found that this mutation was associated with abnormalities in spine morphology (even if less pronounced than for Shank3 STOP ). We then assessed whether Shank3 could have a role earlier in neuronal development. Indeed, Shank3 is expressed in the 
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S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P brain at early stages, 34 and Shank and cortactin are enriched within the lamellipodia of motile cells and in neuronal growth cones. 12, 35 We analyzed the localization of endogenous or overexpressed Shank3 in cultured hippocampal neurons by immunocytochemistry in early stages (Figures 5a and b) . Endogenous Shank3 was detected in young neurons (day 2), and labeling with actin revealed the accumulation of the protein in ruffles. We also confirmed the colocalization of Shank3 and cortactin in axonal growth cones. Then, we tested whether Shank3 regulated growth cone dynamics by co-transfecting GFP-C3 with GFP-Shank3
WT or with the mutated forms in young hippocampal neurons. Four days after the transfection, live cell imaging was performed, as described. 28 The axonal growth cone motility was quantified as a dimensionless motility index. We quantified the mean value of motility index for 35-67 axonal growth cones for each construct (Figures 5c  and d) . We observed an increase of motility index with Shank3
WT compared with the control (0.129±0.005 for Shank3 WT to 0.101±0.005 for GFP-C3; ***P < 0.001). This suggests that full-length Shank3 induces higher axonal growth cone motility. We did not observe such an increase for GFPShank3 Q321R or GFP-Shank3 STOP (0.106 ± 0.003 and 0.112 ± 0.004; 111P < 0.001). Together, these data suggest that these two de novo mutations, Shank3 Q321R and Shank3 STOP , affect neuronal motility during development.
Discussion
Three important conclusions can be drawn from this study. First, we found that Shank3 increases actin polymerization, promoting spine formation and increasing the frequency of mEPSPs. Second, we demonstrated that Shank3 mutations identified in ASD disrupt these processes, providing a cellular readout for Shank3-associated pathologies. Third, we described two de novo mutations, Shank3 Q321R and Shank3 STOP , which were associated with severe loss of S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P G F P -C 3 S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P Shank3 promotes spine formation and shape via an actin-dependent mechanism Spine structure is regulated by various molecular mechanisms, and actin polymerization is a crucial process for synaptic structure and function. 36 Actin filaments in the spine head are highly dynamic and regulate the molecular organization of the postsynaptic density and modulate postsynaptic signal transduction. [37] [38] [39] Our data on neuronal cultures show that Shank3 overexpression induces an increase in spine density associated with an F-actin accumulation and an increase in mEPSP frequency. These effects could be mediated, in part, by a regulation of capping proteins, as we demonstrated that Shank3 colocalized with vinculin and phospho-paxillin at the tip of actin stress fibers in fibroblasts. These capping proteins control the growth of actin filaments in lamellipodia, resulting in filopodia formation and a reduction in lamellipodia. 40 In mature neurons, they localize throughout dendritic spines, 41 similar to Shank3. Furthermore, the Shank complex could be linked to several other proteins regulating actin cytoskeleton dynamics, such as b-Pix, a guanine nucleotide exchange factor for Rac1 and cdc42 small GTPases; 18 Abp1, a member of the Arp2/3 complex; 17 and cortactin. 35 Indeed, depletion of the Arp2/3 complex, including cortactin, Abi2, WAVE-1, N-WASP and Abp1, alters the morphology and number of spines. 13, [42] [43] [44] [45] Altogether, these results suggest that Shank3 could directly regulate F-actin level in spines, resulting in a modification of the shape and the function of these spines.
In this study, we observed increased spine density and morphology with Shank3, which is consistent with previous results obtained in aspiny neurons with Shank3. 22 Shank1B induces an enlargement of spine heads independently of spine density, and this enlargement is enhanced by coexpression of the long form of Homer. 21, 43, 46 Recent data on Shank1 knockout mice suggest that Shank1 is not required for spine formation but promotes the growth and stability of large spines, which is consistent with in vitro results. 47 Shank2 also affects spine head maturation, depending on the Arp2/3 complex. 30 Therefore, it is now clearly established that Shank proteins are involved in spinogenesis, especially in spine maturation, and we highlighted in this study that this occurs via an actin-dependent mechanism.
Shank3 mutations associated with ASD disrupt its cellular functions We showed that de novo or inherited Shank3 mutations associated with ASD can affect its localization at the tip of the F-actin fibers, subsequently disrupting spine formation and morphology. This effect was especially strong for Shank3 STOP and was similar to that observed in hippocampal neurons where Shank3 was downregulated (this study and Grabrucker et al.
23
) or in cerebellar neurons transfected with Shank3 bearing a mutation in the Homerbinding site. 22 This mutation appears to have a dominant-negative effect on the induction and the maturation of spines in a wild-type background (Figure 2b ). This could be due to interference with the localization of other binding partners and/or to PDZ domain dimerization of the mutated form with the endogenous Shank3. 48 Our results highlight the potential impact of the two de novo mutations of Shank3 on early stages of neuronal development. We showed that the endogenous as well as the overexpressed Shank3 was localized in the growth cones of young neurons, suggesting that Shank3 could participate in neurite extension. Consistent with this idea, cortactin mediates neurite outgrowth, 13 and the depletion of Abp1, a linker of Shank3 to the actin complex, results in increased axon length in early stages of neuronal development. 49 The Shank3 STOP and Shank3 S h a n k 3 W T S h a n k 3 R 1 2 C S h a n k 3 R 3 0 0 C S h a n k 3 Q 3 2 1 R S h a n k 3 S T O P SHANK3 mutations in autism and spine morphology CM Durand et al which could lead to disrupted connectivity in patients carrying either mutation. These results are consistent with a recent study showing that the lack of C-terminal domains (including Homer-and cortactin-binding sites, and the SAM domain) inhibits the induction of neurite outgrowth. 50 Inherited mutations represent risk factors for ASD Mutations in SHANK3, including de novo mutations, de novo copy number variations and inherited mutations, have been frequently reported in patients. 6, 7, 50 The importance of the Shank family for ASD was further strengthened by the recent identification of mutations in SHANK2 in ASD patients. 51, 52 If the impact of de novo deleterious mutations is well established, the role of inherited mutations remains unclear. Here, we showed that the two inherited mutations, Shank3 R12C and Shank3
R300C
, have intermediate effects, mainly on spine formation. These results suggest that despite their transmission from healthy parents, these mutations could cause subtle synaptic defects, increasing the risk of developing ASD. SHANK3 mutations can also be involved in other neurological disorders, such as intellectual disability and schizophrenia. 50 In the case of schizophrenia, the de novo mutation R1117X with germline mosaicism has been observed in three affected brothers. They presented mild-to-moderate intellectual disability and schizoaffective disorder, but no evidence of autistic features. Functional studies have confirmed that this mutation causes a loss of SHANK3 function in zebrafish and decreases neurite outgrowth in mice. 50 It is unclear how similar mutations can lead to different clinical conditions. The same is true not only for mutations in NLGN3 and NLGN4 described in autism but also in intellectual disability, Asperger syndrome and Tourette syndrome with hyperactivity disorder. [53] [54] [55] Mutations in NRXN1 have also been observed in patients with schizophrenia and in asymptomatic carriers. 56 These different outcomes could be due to mutations altering either all or specific roles of these proteins (for example, axonal guidance and synapse formation). We can also expect that additional genetic/epigenetic and environmental risk factors acting at different levels of brain development could bias the phenotype toward different sets of disorders. 57 The identification of such factors would allow us to better understand the nature of the biological mechanisms underlying these different disorders and to provide insight for new treatments.
